April 24, 2015
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-4561
Attention: Matthew Jones
Re: | Biondvax Pharmaceuticals Ltd. |
Registration Statement on Form F-1
Filed April 8, 2015
File No. 333-201283
Dear Mr. Jones:
BiondVax Pharmaceuticals Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement so that such Registration Statement shall become effective on April 28, 2015, at 5:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable.
The Company hereby acknowledges that:
● | should the Securities and Exchange Commission (the “Commission”)or thestaff,actingpursuantto delegatedauthority,declarethe filingeffective, itdoesnot foreclose the Commission fromtakinganyaction with respect tothe filing; | |
● | theaction ofthe Commission orthe staff, actingpursuantto delegatedauthority, in declaringthefilingeffective, does notrelievetheCompanyfrom its full responsibilityfor theadequacyandaccuracyof thedisclosureinthe filing; and | |
● | theCompanymaynot assert staffcomments and thedeclaration ofeffectiveness as a defense inanyproceedinginitiatedbythe Commission or anyperson under the federal securities laws oftheUnited States. |
Very truly yours, | |
/s/ Ron Babecoff | |
Ron Babecoff | |
Chief Executive Officer |